Short answer · Medically reviewed summary · Last updated: 2026-05-08
The primary treatment for Recurrent Respiratory Papillomatosis (RRP) is surgical removal of the papillomas to maintain a clear airway, often supplemented with adjuvant therapies for aggressive disease. Because RRP is a chronic condition caused by Human Papillomavirus (HPV) infection, management is highly individualized and focuses on balancing airway patency with the preservation of voice quality. What are the standard surgical and medical treatments for RRP? For most patients with Recurrent Respiratory Papillomatosis, surgery remains the gold standard to debulk lesions.
3 people with Recurrent Respiratory Papillomatosis have shared their first-person experience on this question at DiseaseMaps.
The primary treatment for Recurrent Respiratory Papillomatosis (RRP) is surgical removal of the papillomas to maintain a clear airway, often supplemented with adjuvant therapies for aggressive disease. Because RRP is a chronic condition caused by Human Papillomavirus (HPV) infection, management is highly individualized and focuses on balancing airway patency with the preservation of voice quality.
For most patients with Recurrent Respiratory Papillomatosis, surgery remains the gold standard to debulk lesions. Surgical techniques include cold-instrument micro-laryngoscopy, carbon dioxide (CO2) laser excision, or microdebrider-assisted laryngoscopy. When surgery alone is insufficient due to rapid regrowth, physicians may introduce adjuvant medical therapies to slow the progression of Recurrent Respiratory Papillomatosis. These may include intralesional injections of cidofovir (Vistide) or, more recently, systemic therapies such as bevacizumab (Avastin) to inhibit tumor vascularization.
Managing Recurrent Respiratory Papillomatosis requires a multidisciplinary approach to address both physical health and quality of life. An effective care team typically includes:
Recent research for Recurrent Respiratory Papillomatosis has shifted toward immunomodulatory treatments. Clinical trials are currently investigating the use of programmed cell death protein 1 (PD-1) inhibitors and therapeutic HPV vaccines aimed at stimulating the immune system to recognize and clear the virus. While these are promising, they remain largely in experimental stages and are not yet considered standard of care for all patients with Recurrent Respiratory Papillomatosis.
The clinical course of Recurrent Respiratory Papillomatosis is notoriously unpredictable. Some individuals experience spontaneous remission, while others require surgeries every few months. Factors such as the specific HPV subtype (typically HPV-6 or HPV-11), the patient's immune response, and the anatomical extent of the papillomas significantly influence how well a patient responds to standard treatment protocols.
Medical disclaimer: This information is for educational purposes and does not replace professional medical advice; please consult your physician for diagnosis and treatment decisions.